The pharmacokinetics of valganciclovir prophylaxis in pediatric solid organ transplant patients at risk for Epstein–Barr virus disease

Antiviral prophylaxis with valganciclovir is used frequently in pediatric solid organ transplant patients to prevent Epstein–Barr virus (EBV)-induced infections and tissue-invasive disease including post-transplant lymphoproliferative disorder (PTLD). This approach is untested in clinical trials and...

Descripción completa

Detalles Bibliográficos
Autores principales: Vezina, Heather E, Brundage, Richard C, Nevins, Thomas E, Balfour, Henry H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2009
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262369/
https://www.ncbi.nlm.nih.gov/pubmed/22291482

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262369/
https://www.ncbi.nlm.nih.gov/pubmed/22291482

Ejemplares similares